Undecimal launches with $18M; Erlich reports mouse mRNA repression
Yaniv Erlich, in answers relayed by Lily Jeffery, told RuntimeWire that siRNA screen hits produced statistically significant target-mRNA repression in mice after subcutaneous delivery to extrahepatic tissues, but public materials omit key experimental details.
By Emerson Redding · Published
Why it matters
Erlich’s account, if supported by underlying data, would make the broad “in-vivo validated” label more concrete by describing a route, species and target-mRNA outcome. The reported result is limited to mice and target-mRNA repression; it does not establish human delivery, safety, therapeutic efficacy or benefit in renovascular disease.
Undecimal Bio announced an oversubscribed $18 million seed round, saying the funding would support development of its DELiveri platform, renovascular programs and team expansion at laboratories based at the Cancer Research UK Cambridge Institute. The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures and Saras Capital, according to the financing announcement.…